Expert perspectives and practical guidance on targeting MET in advanced NSCLC

Expert perspectives and practical guidance on targeting MET in advanced NSCLC
June 3, 2021 ology
Current Status
Not Enrolled
Price
Free
Get Started

Learn from leading experts about: the different types, and clinical implications, of mesenchymal–epithelial transition (MET) dysregulations in patients with advanced non-small-cell lung cancer (NSCLC); why advanced diagnostic techniques are helpful for an early identification of these dysregulations; and how to implement individualized evidence-based treatment plans.

This activity is supported by an independent educational grant from Merck KGaA, Darmstadt, Germany.